11 results about "Desonide" patented technology

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

The application provides a drug delivery system and a preparation method and application thereof, and relates to the technical field of biomedicine.The drug delivery system comprises mesenchymal stem cell exosomes, black phosphorus quantum dots and budesonide.The drug delivery system contains mesenchymal stem cell exosomes, has the functions of immune regulation, anti-inflammation and lung targeting, realizes lung targeted delivery of the black phosphorus quantum dots loaded with budesonide, and realizes precise regulation of lung temperature by utilizing the near-infrared photothermal effect of the black phosphorus quantum dots in asthma for the first time, so that local hyperthermia for allergic asthma is realized.The drug delivery system utilizes the photothermal effect of the black phosphorus quantum dots in the carrier to control the release speed of budesonide, is beneficial to maintaining the optimal drug concentration in the lung, and is expected to reduce the dosage and frequency of medication and reduce the risk of side effects.The application firstly cooperates the mesenchymal stem cell exosomes, local hyperthermia and the immune regulation effect of budesonide for the treatment of allergic asthma.

The present application relates to the technical field of medicine, and in particular to a budesonide-loaded oral colon-targeted delivery system, a preparation method and application. The delivery system takes Pickering emulsion-encapsulated budesonide as the core, and is sequentially coated with a low-ester pectin-calcium ion crosslinked inner layer and a low-ester pectin-chitosan polyelectrolyte complex outer layer. The preparation process is realized by combining an emulsion template method with layer-by-layer self-assembly technology. The obtained microcapsules have a uniform spherical structure, a particle size of about 400 μm, and a double-layer three-dimensional network structure. The delivery system remains stable in the gastrointestinal environment, and only releases drugs rapidly under colon pH conditions. In vitro simulation experiments show that the drug release rate is less than 5% in the stomach / small intestine stage, and is rapidly released in the colon stage. Animal experiments confirm that the effect of treating ulcerative colitis is equivalent to that of mesalamine, while the systemic toxicity is significantly reduced, the drug retention time at the colon site is more than 24 hours, and there is no accumulation in non-target organs.

The invention discloses a budesonide-loaded ginseng vesicle delivery system and a construction method and application thereof, and belongs to the technical field of plant-derived nano-drug delivery systems. According to the delivery system, nano-vesicles from ginseng are taken as carriers, and budesonide is entrapped to form a BUD-coated GDNPs compound. The delivery system can synergistically enhance the anti-inflammatory effect of budesonide, significantly alleviate airway inflammation of asthma model animals, reduce side effects such as blood glucose disorder and the like caused by high-dose budesonide, and has excellent biological safety. The delivery system provided by the invention can be used for clinical treatment of asthma, is especially suitable for patients who need to use glucocorticoid for a long time, solves the technical problems of low bioavailability and obvious side effects of traditional budesonide, and has important clinical application value and industrialization prospect.

The invention relates to the technical field of pharmaceutical preparations, in particular to a stable desonide lotion and a preparation method thereof. The desonide lotion is prepared from the following components in percentage by weight: 0.5 to 1.2 percent of desonide, 0.2 to 0.6 percent of a functional additive, 2 to 6 percent of span 80, 1 to 3 percent of dimethyl silicone oil, 2 to 5 percent of glycerol, 2 to 3 percent of asiaticoside, 3 to 6 percent of glycerol monostearate, 2 to 3 percent of squalane, 3 to 5 percent of tragacanth, 0.5 to 1 percent of fumed silica, 0.05 to 0.1 percent of tartaric acid, 0.08 to 0.12 percent of citric acid, 2 to 4 percent of a wetting agent, 0.08 to 0.2 percent of a preservative, 0.2 to 0.5 percent of an antioxidant and the balance of water. According to the functional additive prepared by a specific method, a porous titanium dioxide ball is used as a carrier, and a norfloxacin derivative is bonded on the surface and in a pore channel of the porous titanium dioxide ball through a photochemical grafting technology; the use of the functional additive effectively improves the antibacterial property and photosensitivity of the desonide lotion, so that the prepared desonide lotion not only is highly stable, but also has anti-inflammatory and antibacterial effects, is excellent in comprehensive performance, and has very high market application value.

The invention discloses a medicinal composition for treating dermatitis and a preparation method and application thereof, and relates to the technical field of medicines.The medicinal composition is cream, the medicinal composition comprises vitamin E and desonide, based on the total weight of the cream, the content of the desonide is 0.0025%-0.045%, preferably 0.025%, and the content of the vitamin E is 0.025%-0.045%, preferably 0.025%. The invention aims to solve the technical problem that a desonide vitamin E compound emulsifiable paste preparation which is specially designed for infant atopic dermatitis and is low in concentration, fixed in proportion and stable in quality is lacked in the prior art.

The invention relates to a desonide composition with improved stability, which is an emulsion type topical pharmaceutical preparation composition with a pH value of 3.7-4.5, and comprises 0.005-0.5% w / w of desonide, an oil phase comprising a surfactant and a combination of a self-emulsifier and a surface active emulsifier, and a water phase comprising a humectant, a preservative and a chelating agent. By reducing the pH value, the stability of the composition can be effectively improved. The composition has the advantages that the components and the preparation method are reasonable in design, the stability of the composition can be effectively improved by adjusting the pH value on the basis of improving skin conditions (such as inflammation and pruritus) of skin diseases, and the composition has equivalence with commercially available products.

1. The name of the design product: medicine packaging box (denile soft paste). 2. The use of the design product: packaging medicine. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view.

The invention provides an in-vitro release test method for desonide ointment. The in-vitro release test method comprises the following steps: (1) releasing a desonide component in the desonide ointment by using an in-vitro transdermal instrument; (2) determining through high performance liquid chromatography; and (3) calculating the release amount of the desonide ointment by using a standard curve method. The step (1) is specifically as follows: a test device is based on a Franz diffusion cell method; a proper inert and commercialized artificial film is installed in the Franz diffusion cell system; setting in-vitro release test parameters; and testing an in-vitro release test of the model medicine.

This invention relates to a desonide lotion and its preparation method. The desonide lotion comprises desonide, an oil phase component, a humectant, a surfactant, 1,3-butanediol, propylene glycol alginate, a preservative, and water. Specifically, the desonide lotion is composed of desonide, liquid paraffin, dimethyl silicone oil, glycerin, Span 80, sodium dodecyl sulfate, 1,3-butanediol, propylene glycol alginate, methylparaben, propylparaben, and water. This invention, by combining 1,3-butanediol and propylene glycol alginate as a stabilizing matrix and functional additive, has successfully developed a desonide lotion with excellent physicochemical stability, good spreading and wetting properties, high transdermal absorption rate, and a simple preparation process, possessing extremely high clinical value and promising industrial application prospects.

Disclosed is a spray device for nasal or buccal delivery of a buffered aqueous composition comprising solubilized budesonide, the composition having improved long term storage stability and reduced amounts of impurities, the buffering agent being adjusted to pH 4 to 5, where budesonide is dissolved at a concentration of at least 100 / vg / mL, where the composition is free of metal ions, and where the budesonide is dissolved at a concentration of at least 100 / vg / mL. The present invention relates to a composition comprising solubilized budesonide and packaged in a metal-free first container closed with an atomizing pump system, said metal-free first container being packaged in a sealed oxygen-impermeable, oxygen-free second container, and wherein the composition comprises at least 90%, preferably at least 95%, of the nominal initial concentration of the solubilized budesonide after storage at 25 DEG C for a period of 12 months, preferably at least 90%, preferably at least 90%, of the nominal initial concentration of the solubilized budesonide, preferably at least 90%, of the nominal initial concentration of the solubilized budesonide. And total impurities at a concentration of not more than 1% relative to budesonide. The invention further relates to a composition for use as a medicament for the treatment of inflammatory diseases or conditions.